ID

34540

Beschrijving

Pharmacokinetics of Degarelix in Chinese Patients With Prostate Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT02468284

Link

https://clinicaltrials.gov/show/NCT02468284

Trefwoorden

  1. 19-01-19 19-01-19 -
  2. 22-05-19 22-05-19 -
Houder van rechten

see on clinicaltrials.gov

Geüploaded op

19 januari 2019

DOI

Voor een aanvraag inloggen.

Licentie

Creative Commons BY-NC 3.0

Model Commentaren :

Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.

Itemgroep Commentaren voor :

Item Commentaren voor :

U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.

Eligibility Prostate Cancer NCT02468284

Eligibility Prostate Cancer NCT02468284

Inclusion Criteria
Beschrijving

Inclusion Criteria

Alias
UMLS CUI
C1512693
has a histologically confirmed (gleason graded) adenocarcinoma of the prostate (all stages), for which endocrine therapy (except for neoadjuvant hormonal therapy) is indicated
Beschrijving

ID.1

Datatype

boolean

has a prostate-specific antigen (psa) level ≥2.0 ng/ml at screening
Beschrijving

ID.2

Datatype

boolean

has a screening serum testosterone level >150 ng/dl
Beschrijving

ID.3

Datatype

boolean

has an eastern cooperative oncology group (ecog) score of ≤2
Beschrijving

ID.4

Datatype

boolean

Exclusion Criteria
Beschrijving

Exclusion Criteria

Alias
UMLS CUI
C0680251
has had previous or is currently under hormonal management of prostate cancer. however, hormonal therapy for a maximum duration of 6 months is accepted. this treatment should have been terminated at least 6 months prior to the screening visit
Beschrijving

ID.5

Datatype

boolean

is currently treated with a 5-alpha reductase inhibitor
Beschrijving

ID.6

Datatype

boolean

is considered to be candidate for curative therapy, i.e. radical prostatectomy or radiotherapy
Beschrijving

ID.7

Datatype

boolean

is in need of neoadjuvant hormonal therapy
Beschrijving

ID.8

Datatype

boolean

has a history of bilateral orchiectomy, adrenalectomy, or hypophysectomy
Beschrijving

ID.9

Datatype

boolean

Similar models

Eligibility Prostate Cancer NCT02468284

Name
Type
Description | Question | Decode (Coded Value)
Datatype
Alias
Item Group
C1512693 (UMLS CUI)
ID.1
Item
has a histologically confirmed (gleason graded) adenocarcinoma of the prostate (all stages), for which endocrine therapy (except for neoadjuvant hormonal therapy) is indicated
boolean
ID.2
Item
has a prostate-specific antigen (psa) level ≥2.0 ng/ml at screening
boolean
ID.3
Item
has a screening serum testosterone level >150 ng/dl
boolean
ID.4
Item
has an eastern cooperative oncology group (ecog) score of ≤2
boolean
Item Group
C0680251 (UMLS CUI)
ID.5
Item
has had previous or is currently under hormonal management of prostate cancer. however, hormonal therapy for a maximum duration of 6 months is accepted. this treatment should have been terminated at least 6 months prior to the screening visit
boolean
ID.6
Item
is currently treated with a 5-alpha reductase inhibitor
boolean
ID.7
Item
is considered to be candidate for curative therapy, i.e. radical prostatectomy or radiotherapy
boolean
ID.8
Item
is in need of neoadjuvant hormonal therapy
boolean
ID.9
Item
has a history of bilateral orchiectomy, adrenalectomy, or hypophysectomy
boolean

Gebruik dit formulier voor feedback, vragen en verbeteringsvoorstellen.

Velden gemarkeerd met een * zijn verplicht.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial